Zobrazeno 1 - 10
of 304
pro vyhledávání: '"Leleu, A."'
Autor:
Meletios A. Dimopoulos, Fredrik Schjesvold, Vadim Doronin, Olga Vinogradova, Hang Quach, Xavier Leleu, Yolanda Gonzalez Montes, Karthik Ramasamy, Alessandra Pompa, Mark-David Levin, Cindy Lee, Ulf Henrik Mellqvist, Roland Fenk, Hélène Demarquette, Hamdi Sati, Alexander Vorog, Richard Labotka, Jichang Du, Mohamed Darif, Shaji Kumar
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 1, Pp 1-10 (2022)
Blood Cancer Journal
Blood Cancer Journal
Multiple myeloma (MM) patients typically receive several lines of combination therapy and first-line treatment commonly includes lenalidomide. As patients age, they become less tolerant to treatment, requiring convenient/tolerable/lenalidomide-free o
Autor:
Hani Hassoun, Jacob P. Laubach, Jan S. Moreb, Sara Thuresson, Paula Rodriguez-Otero, Marcus Thuresson, Michele Cavo, Albert Oriol, Maria-Victoria Mateos, Joan Bladé, John W. Hiemenz, Adrian Alegre, Amitabha Mazumder, Horizon (Op ) Investigators, Kenneth C. Anderson, Omar Nadeem, Johan Harmenberg, Nicolaas A Bakker, Xavier Leleu, Alessandra Larocca, Christopher Maisel, Paul G. Richardson, Agne Paner, Anastasios Raptis, Cyrille Touzeau, Catriona Byrne
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Journal of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen
Autor:
Gilles Rioufol, François Dérimay, François Roubille, Thibault Perret, Pascal Motreff, Denis Angoulvant, Yves Cottin, Ludovic Meunier, Laura Cetran, Guillaume Cayla, Brahim Harbaoui, Jean-Yves Wiedemann, Éric Van Belle, Christophe Pouillot, Nathalie Noirclerc, Jean-François Morelle, François-Xavier Soto, Christophe Caussin, Bernard Bertrand, Thierry Lefèvre, Patrick Dupouy, Pierre-François Lesault, Franck Albert, Olivier Barthelemy, René Koning, Laurent Leborgne, Pierre Barnay, Philippe Chapon, Sébastien Armero, Antoine Lafont, Christophe Piot, Camille Amaz, Bernadette Vaz, Lakhdar Benyahya, Yvonne Varillon, Michel Ovize, Nathan Mewton, Gérard Finet, Alexandre Fournier, Geneviève Jarry, François Leleu, Dorothée Malaquin, Anfani Mirode, Loïc Belle, Lionel Mangin, Jean-Lou Hirsch, Marc Metge, Michel Pansiery, FrançoisXavier Soto, Antoine Boge, Kamel HadjHamou, Ichem Miliani, Guillaume Molins, Stéphane Mourot, Marion Pelletier, Olivier Ressencourt, Frédéric Schaad, Pierre Coste, Warren Chasseriaud, Pierre Poustis, Jean-Francois Morelle, Thibaud Demicheli, Grégroire Range, Christophe Thuaire, Nicolas Barber-Chamoux, Nicolas Combaret, Guilhem Malclès, Géraud Souteyrand, Philippe Buffet, Aurélie Gudjonvick, Isabelle L’Huillier, Luc Lorgis, Carole Richard, Gilles Baronne-Rochette, Hélène Bouvaist, Stéphanie Marlière, Olivier Ormezzano, Gérald Vanzetto, Charlotte Trouillet, Yann Valy, Eric VanBelle, Christophe Bauters, Cédric Delhaye, Gilles Lemesle, Riadh Rihani, Pierre Graux, Jean-Michel Lemahieu, Cyril Besnard, Pierre-Yves Courand, Raphaël Dauphin, Pierre Lantelme, Jean-Raymond Caignault, Olivier Dubreuil, Sylvain Ranc, Bernard Ritz, Cyrille Bergerot, Thomas Bochaton, Eric Bonnefoy-Cudraz, Didier Bresson, Julie Dementhon, François Derimay, Lisa Green, Cyril Prieur, Ingrid Sanchez, Oualid Zouaghi, Sébastien Arméro, Hakim Ben-Amer, Bernard Chevalier, Philippe Garot, Thomas Hovasse, Yves Louvard, Marie-Claude Morice, Oscar Tavolaro, Thierry Unterseeh, DinhThienTri Cung, Jean-Christophe Macia, Gilles Levy, Olivier Roth, Laurent Jacquemin, Luc Cornillet, Bertrand Ledermann, Laurent Schmutz, Nicole Karam, Saliha Rahal, Nicolas Amabile, Philippe Girard, Aurélie Veugeois, Olivier Barthélémy, Jean-Philippe Collet, Gilles Montalescot, Jacques Berland, Matthieu Godin, Quentin Landolff, Bilel Zoghlami, Karim Bougrini, Christophe Geyer, Jens Glanenapp, Patrick Mascarel, Geoffray Rambaud, Richard ViFane, Bernard Desveaux, Fabrice Ivanes, Gérard Pacouret, Laurent-Emmanuel Quilliet, Christophe SaintEtienne, Christophe Bretelle, Stanislas Champin
Publikováno v:
Journal of the American College of Cardiology
Journal of the American College of Cardiology, Elsevier, 2021, 78 (19), pp.1875-1885. ⟨10.1016/j.jacc.2021.08.061⟩
Journal of the American College of Cardiology, Elsevier, 2021, 78 (19), pp.1875-1885. ⟨10.1016/j.jacc.2021.08.061⟩
Background There is limited evidence that fractional flow reserve (FFR) is effective in guiding therapeutic strategy in multivessel coronary artery disease (CAD) beyond prespecified percutaneous coronary intervention or coronary graft surgery candida
Autor:
Shaji Kumar, Maria Delioukina, Torben Plesner, Noopur Raje, Jessica Vermeulen, Hartmut Goldschmidt, Supratik Basu, Hang Quach, Rian Van Rampelbergh, Saad Z. Usmani, Xavier Leleu, Aurore Perrot, Thierry Facon, Jianping Wang, Tahamtan Ahmadi, Michael O'Dwyer, Clarissa M. Uhlar, Katja Weisel, Cyrille Hulin, Robert Z. Orlowski, Brenda Tromp, Philippe Moreau, Christopher P. Venner, Joseph R. Mace, Mourad Tiab, Margaret Macro, Laurent Frenzel, Hareth Nahi, Nizar J. Bahlis
Publikováno v:
Facon, T, Kumar, S K, Plesner, T, Orlowski, R Z, Moreau, P, Bahlis, N, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O'Dwyer, M, Perrot, A, Venner, C P, Weisel, K, Mace, J R, Raje, N, Tiab, M, Macro, M, Frenzel, L, Leleu, X, Ahmadi, T, Wang, J, Van Rampelbergh, R, Uhlar, C M, Tromp, B, Delioukina, M, Vermeulen, J & Usmani, S Z 2021, ' Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA) : overall survival results from a randomised, open-label, phase 3 trial ', The Lancet Oncology, vol. 22, no. 11, pp. 1582-1596 . https://doi.org/10.1016/S1470-2045(21)00466-6
Background: In the primary analysis of the phase 3 MAIA trial (median follow-up 28·0 months), a significant improvement in progression-free survival was observed with daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethas
Autor:
Hans C. Lee, Saad Z. Usmani, Robert M. Rifkin, Dasha Cherepanov, Evangelos Terpos, Faith E. Davies, Dorothy Romanus, Antonio Palumbo, Aditya Raju, Jesus G. Berdeja, Dawn Marie Stull, Noemi Puig, Jorge Vela-Ojeda, Rafat Abonour, Xavier Leleu, Hui Huang, Ajai Chari, Eileen Farrelly, Mario Boccadoro, Gordon Cook, Katja Weisel, Gareth J. Morgan, Caitlin Costello, Jeffrey A. Zonder, Marlo Blazer, Michael A. Thompson, Roman Hájek
Publikováno v:
Annals of Hematology
Multiple available combinations of proteasome inhibitors, immunomodulators (IMIDs), and monoclonal antibodies are shifting the relapsed/refractory multiple myeloma (RRMM) treatment landscape. Lack of head-to-head trials of triplet regimens highlights
Autor:
Michel Attal, Xavier Leleu, Salomon Manier, Lotfi Benboubker, Clara Mariette, Cécile Sonntag, Karim Belhadj, Denis Caillot, Cyrille Touzeau, Martine Escoffre-Barbe, Benjamin Hebraud, Laurent Garderet, Soraya Wuilleme, Philippe Moreau, Jill Corre, Valérie Lauwers-Cances, Thierry Facon, Jehan Dupuis, Murielle Roussel
Publikováno v:
Blood. 138:113-121
Bortezomib, lenalidomide, and dexamethasone plus transplant is a standard of care for eligible patients with multiple myeloma. Because responses can deepen with time, regimens with longer and more potent induction/consolidation phases are needed. In
Autor:
Effie W Petersdorf, Mary Carrington, Colm O'hUigin, Mats Bengtsson, Dianne De Santis, Valerie Dubois, Ted Gooley, Mary Horowitz, Katharine Hsu, J Alejandro Madrigal, Martin J Maiers, Mari Malkki, Caroline McKallor, Yasuo Morishima, Machteld Oudshoorn, Stephen R Spellman, Jean Villard, Phil Stevenson, Martin Maiers, Stephen Spellman, Jane Apperley, Peter Bardy, Ghislaine Bernard, Yves Bertrand, Adrian Bloor, Chiara Bonini, Stephane Buhler, Laura Bungener, Helen Campbell, Kristina Carlson, Ben Carpenter, Anne Cesbron, Christian Chabannon, Yves Chalandon, Jeremy Chapman, Réda Chebel, Patrice Chevallier, Gerda Choi, Matt Collin, Jan J Cornelissen, Charles Crawley, Lloyd D'Orsogna, Jean-Hugues Dalle, Eric Deconinck, Muriel DeMatteis, Mary Diviney, Anne Dormoy, Katia Gagne, Brenda Gibson, Maria Gilleece, David Gottlieb, John Gribben, Tayfun Güngör, Mike Haagenson, Cathie Hart, Rhonda Holdsworth, Ian Humphreys, Yoshihisa Kodera, Mickey Koh, Hélène Labussière-Wallet, Arjan C Lankester, Neubery Lardy, Sarah Lawson, Xavier Leleu, Stephen MacKinnon, Ram Malladi, Steven GE Marsh, Murray Martin, Neema P Mayor, I Grant McQuaker, Ellen Meijer, Satoko Morishima, Emmanouil Nikolousis, Kim Orchard, Jacob Passweg, Amit Patel, Katherine Patrick, Béatrice Pedron, Andy Peniket, Julia Perry, Eefke Petersen, Victoria Potter, Mike Potter, Rachel Protheroe, Nicole Raus, Carmen Ruiz de Elvira, Nigel Russell, Nicholaas PM Schaap, Urs Schanz, Harry Schouten, Roderick Skinner, John Snowden, Eric Spierings, Colin Steward, Eleni Tholouli, Alycia Thornton, Marcel Tilanus, Arnold van de Meer, Hendrik Veelkens, Paul Veys, Narelle Watson, Lyanne Weston, Keith Wilson, Marie Wilson, Robert Wynn, József Zsiros
Publikováno v:
The Lancet Haematology
The Lancet Haematology, Elsevier, 2021, 7 (1), pp.e50-e60. ⟨10.1016/s2352-3026(19)30208-x⟩
Petersdorf, E W, Carrington, M, O'hUigin, C, Bengtsson, M, De Santis, D, Dubois, V, Gooley, T, Horowitz, M, Hsu, K, Madrigal, J A, Maiers, M J, Malkki, M, McKallor, C, Morishima, Y, Oudshoorn, M, Spellman, S R, Villard, J, Stevenson, P & International Histocompatibility Working Group in Hematopoietic Cell Transplantation 2020, ' Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation : a retrospective cohort study ', The Lancet Haematology, vol. 7, no. 1, pp. e50-e60 . https://doi.org/10.1016/S2352-3026(19)30208-X
The Lancet Haematology, 7(1), e50-e60. Lancet Publishing Group
The Lancet. Haematology, Vol. 7, No 1 (2020) pp. e50-e60
The Lancet Haematology, 7(1), E50-E60. ELSEVIER SCI LTD
The Lancet Haematology, 7(1), e50. Lancet Publishing Group
Lancet Haematol
The Lancet Haematology, Elsevier, 2021, 7 (1), pp.e50-e60. ⟨10.1016/s2352-3026(19)30208-x⟩
Petersdorf, E W, Carrington, M, O'hUigin, C, Bengtsson, M, De Santis, D, Dubois, V, Gooley, T, Horowitz, M, Hsu, K, Madrigal, J A, Maiers, M J, Malkki, M, McKallor, C, Morishima, Y, Oudshoorn, M, Spellman, S R, Villard, J, Stevenson, P & International Histocompatibility Working Group in Hematopoietic Cell Transplantation 2020, ' Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation : a retrospective cohort study ', The Lancet Haematology, vol. 7, no. 1, pp. e50-e60 . https://doi.org/10.1016/S2352-3026(19)30208-X
The Lancet Haematology, 7(1), e50-e60. Lancet Publishing Group
The Lancet. Haematology, Vol. 7, No 1 (2020) pp. e50-e60
The Lancet Haematology, 7(1), E50-E60. ELSEVIER SCI LTD
The Lancet Haematology, 7(1), e50. Lancet Publishing Group
Lancet Haematol
Background: The success of unrelated haemopoietic cell transplantation (HCT) is limited by graft-versus-host disease (GVHD), which is the main post-transplantation challenge when HLA-matched donors are unavailable. A sequence dimorphism in exon 1 of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::195a18e65915d7d3471d1ddf38d8b61a
https://www.hal.inserm.fr/inserm-03349714/document
https://www.hal.inserm.fr/inserm-03349714/document
Autor:
Stefaan De Smet, Saskia Leleu, Evelyne Delezie, Filip Van Immerseel, Freddy Haesebrouck, Christof Rapp, Joris Michiels, Richard Ducatelle, Annatachja De Grande
Publikováno v:
Journal of Animal Physiology and Animal Nutrition. 105:777-786
The objective of this study was to evaluate the interaction of zinc source (ZnSO4 vs. zinc amino acid complex) and vitamin E level (50 IU vs. 100 IU) on performance and intestinal health of broilers exposed to a temperature challenge in the finisher
Autor:
Dimopoulos, M. A., Špička, I., Quach, H., Oriol, Albert, Hájek, R., Garg, M., Beksac, M., Bringhen, S., Katodritou, E., Chng, W. J., Leleu, X., Iida, S., Mateos, M. V., Morgan, G., Vorog, A., Labotka, R., Wang, B., Palumbo, A., Lonial, S., Universitat Autònoma de Barcelona
Publikováno v:
Journal of Clinical Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Digital.CSIC. Repositorio Institucional del CSIC
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Digital.CSIC. Repositorio Institucional del CSIC
© 2020 by American Society of Clinical Oncology.
[Purpose]: Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has
[Purpose]: Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has
Autor:
Ashraf Badros, Nizar J. Bahlis, Roman Hájek, Larry D. Anderson, Vadim A Doronin, Meletios A. Dimopoulos, Jacqueline Jeha, Halyna Pylypenko, Jatin P. Shah, Reuben Benjamin, Sebastian Grosicki, Maria Gavriatopoulou, Dinesh Kumar Sinha, Xavier Leleu, Thierry Facon, Tuphan Kanti Dolai, Michele Cavo, Don A. Stevens, Moshe Yair Levy, Iryna Kriachok, Sundar Jagannath, L. Pour, Paul G. Richardson, Holger W. Auner, Maria V. Mateos, Sharon Shacham, Sosana Delimpasi, Hang Quach, Yi Chai, Mamta Garg, Michael Kauffman, Ivan Spicka, Maryana Simonova, Philippe Moreau, Christopher P. Venner, Ganna Usenko, Melina Arazy
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in the Phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaf7cc61cc2d359ff206c62213e34e08
http://hdl.handle.net/10044/1/89189
http://hdl.handle.net/10044/1/89189